Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
4.2
30.36%
20%
—
139x
60%
—
5 Years
Score4.2
Net Growth30.36%
Net Trend20%
Net Income Consistency—
Rev Growth139x
Rev Trend60%
Revenue Consistency—
Lexicon Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 23M to $ 49M and net income went from -$ 58M to -$ 50M. Revenue increased in 3 of those 5 years; net income in 1.
Between 2015 and 2025, revenue declined from $ 130M to $ 49M and net income went from -$ 4M to -$ 50M. Revenue increased in 5 of those 10 years; net income in 4.
Lexicon Pharmaceuticals Inc currently holds a 20-year HDB Score of 2.1 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 2.35 | — |
1 Year2025-08-12 | $ 1.06 | 121.70% |
5 Years2021-08-12 | $ 3.80 | -38.16% |
10 Years2016-08-12 | $ 15.95 | -85.27% |
20 Years2006-08-11 | $ 25.83 | -90.90% |
All Time2000-04-07 | $ 131.25 | -98.21% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 | All Time2000-04-07 |
|---|---|---|---|---|---|---|
| Price | $ 2.35 | $ 1.06 | $ 3.80 | $ 15.95 | $ 25.83 | $ 131.25 |
| Return | — | 121.70% | -38.16% | -85.27% | -90.90% | -98.21% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 41M | -$ 61M | $ 190M |
| 2025 | $ 49M | -$ 50M | $ 96M |
| 2024 | $ 31M | -$ 200M | $ 237M |
| 2023 | $ 1M | -$ 177M | $ 170M |
| 2022 | $ 139K | -$ 101M | $ 138M |
| 2021 | $ 298K | -$ 87M | $ 86M |
| 2020 | $ 23M | -$ 58M | $ 152M |
| 2019 | $ 322M | $ 130M | $ 271M |
| 2018 | $ 63M | -$ 120M | $ 160M |
| 2017 | $ 90M | -$ 129M | $ 310M |
| 2016 | $ 83M | -$ 141M | $ 346M |
| 2015 | $ 130M | -$ 4M | $ 521M |
| 2014 | $ 22M | -$ 100M | $ 339M |
| 2013 | $ 2M | -$ 104M | $ 129M |
| 2012 | $ 1M | -$ 110M | $ 223M |
| 2011 | $ 1M | -$ 116M | $ 281M |
| 2010 | $ 4M | -$ 101M | $ 211M |
| 2009 | $ 10M | -$ 82M | $ 162M |
| 2008 | $ 32M | -$ 76M | $ 103M |
| 2007 | $ 50M | -$ 58M | $ 258M |
| 2006 | $ 72M | -$ 54M | $ 79M |
| 2005 | $ 75M | -$ 36M | $ 99M |
| 2004 | $ 61M | -$ 47M | $ 87M |
| 2003 | $ 42M | -$ 64M | $ 104M |
| 2002 | $ 35M | -$ 59M | $ 93M |
| 2001 | $ 305M | -$ 35M | $ 156M |
| IPO2000 | $ 14M | -$ 25M | $ 202M |
Explore beyond LXRX
You're looking at Lexicon Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
